The analysis of immunoreactivity of individual B-cell epitopes of hepatitis C virus (Flaviviridae: Hepacivirus: Hepatitis С virus) NS4a antigen
Authors:
- Lyudmila I. NikolaevaLNLyudmila I. Nikolaeva
- Alexander N. BelyavtsevABAlexander N. Belyavtsev
- Nadezhda G. ShevchenkoNSNadezhda G. Shevchenko
- Maya D. StuchinskayaMSMaya D. Stuchinskaya
- Evgeniy I. SamokhvalovESEvgeniy I. Samokhvalov
- Anna V. DedovaADAnna V. Dedova
- Georgiy V. SapronovGSGeorgiy V. Sapronov
- Nataliya S. ShastinaNSNataliya S. Shastina
- Victor V. KuprianovVKVictor V. Kuprianov
Open Access
- 5 September 2022
- journal article
- research article
- Published by Central Research Institute for Epidemiology in Problems of Virology
- Vol. 67 (3) , 237-245
Abstract
Introduction. Chronic viral hepatitis C (CHC) is a ubiquitous infectious disease, a significant limitation of which WHO attributes to the use of a new highly effective antiviral therapy. Previously, two B-cell epitopes were identified in NS4a antigen of the hepatitis C virus (HCV). It was shown that certain titers of antibodies (ABs) to the extended C-terminal epitope (16871718 a.a.) can predict a high probability of achieving a sustained virological response (SVR) to standard therapy with pegylated interferon- and ribavirin. The aim of the work was to determine immunoreactivity of two B-cell epitopes (middle and C-terminal) of NS4a antigen, and to estimate a possible association of ABs to them with the achievement of SVR after standard interferon therapy and treatment with direct antiviral drugs (DAAs) daclatasvir and sofosbuvir (velpanat). Materials and methods. Blood serum samples of patients with CHC (n = 113), of which 55 participants received standard interferon therapy, 50 received velpanate treatment, the remaining 8 received no therapy were examined. The middle B-cell epitope (positions 2434 a.a.) of NS4a was synthesized by the solid-phase method, while the C-terminal epitope (3454 a.a.) was obtained using genetically engineered techniques. Enzyme immunoassay (ELISA) testing of the sera collected before treatment was performed for the two selected epitopes according to the conventional methods. Results. The antibodies to the C-terminal epitope were detected significantly more frequently than those to the middle one (p = 0.01) when analyzing the blood sera of patients (n = 113). The presence of ABs to the C-terminal epitope in the serum samples of participants who completed standard interferon therapy was associated with the achievement of SVR (p = 0.0245). In the blood sera of participants who completed therapy with velpanate, an association of the presence of ABs to the C-terminal epitope with the achievement of SVR was also established (p 0.0001). The presence of ABs to the middle B epitope was not associated with the achievement of SVR, regardless of the therapy used. Discussion. The observed difference in the immunoreactivity of the two B-cell determinants may be associated with the localization of the nearest Th-epitopes, the sensitivity of NS4a antigen to proteolytic enzymes, and the peculiarities of epitope presentation by antigen-presenting cells. However, it should be noted that the immunoreactivity of the middle B-epitope is poorly studied. Although the association of ABs to the C-terminal epitope with the achievement of SVR has been shown by several scientific teams, the detailed molecular mechanism of their influence on the effectiveness of therapy is unclear. Conclusion. In CHC, ABs to the C-terminal epitope of NS4a are produced more frequently than those to the median epitope. The presence of ABs to the C-terminal epitope is a predictive marker of a high probability of achieving SVR, regardless of the type of therapy and antibody titer.Keywords
This publication has 21 references indexed in Scilit:
- Ultrastructural analysis of hepatitis C virus particlesProceedings of the National Academy of Sciences, 2013
- NS4A protein as a marker of HCV history suggests that different HCV genotypes originally evolved from genotype 1bVirology Journal, 2011
- Baseline anti-NS4a antibodies in combination with on-treatment quantitative HCV-RNA reliably identifies nonresponders to pegylated interferon–ribavirin combination therapy after 4 weeks of treatmentEuropean Journal of Gastroenterology & Hepatology, 2010
- Serum levels of anti-NS4a and anti-NS5a predict treatment response of patients with chronic hepatitis CJournal of Medical Virology, 2007
- Minimal T-Cell-Stimulatory Sequences and Spectrum of HLA Restriction of Immunodominant CD4 + T-Cell Epitopes within Hepatitis C Virus NS3 and NS4 ProteinsJournal of Virology, 2005
- Broad Specificity of Virus-Specific CD4+T-Helper-Cell Responses in Resolved Hepatitis C Virus InfectionJournal of Virology, 2002
- Virus‐specific antibody titres in different phases of hepatitis C virus infectionJournal of Viral Hepatitis, 2002
- Antigenic Heterogeneity of the Hepatitis C Virus NS4 Protein as Modeled with Synthetic PeptidesVirology, 1999
- Distinct Subtypes of Hepatitis C Virus Defined by Antibodies Directed to the Putative Core, NS4, and NS5 Region Polypeptides1994
- DNA sequencing with chain-terminating inhibitorsProceedings of the National Academy of Sciences of the United States of America, 1977